Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a lens put the brakes on worsening Short-Sightedness?

NCT ID NCT07804043

Disease control Sponsor: Fondation Ophtalmologique Adolphe de Rothschild Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 04, 2026 · Last updated Sep 04, 2026

Summary

This trial tests whether special eyeglass lenses, called Stellest 2.0, can slow the progression of short-sightedness (myopia) in young adults compared with standard lenses. Participants will wear either the special lenses or standard ones for at least 12 hours a day for two years. Researchers will measure changes in eye length and prescription strength to see if the special lenses make a difference. They will also check how comfortable the lenses are during the first few months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Essilor Stellest 2.0 myopia-slowing eyeglass lenses
What this could lead to
If effective, these lenses could offer a non-invasive way to slow myopia worsening in young adults, potentially reducing the need for stronger prescriptions and lowering the risk of eye complications later in life.
What could go wrong
The trial is relatively small and focuses on young adults, so results may not apply to other age groups. The lenses may not slow myopia as much as hoped, and some people might find them uncomfortable to wear for the required 12 hours a day.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 134 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2026

An estimate. Start dates often move.

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

16 to 25 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Spherical equivalent (SE) measured under cycloplegia using an autorefractometer, within the range 4 D ≤ SE ≤ -0.75 D for each eye * Not currently receiving, nor having received, any preventive treatment for myopic progression in the 12 months prior to inclusion (orthokeratology, soft defocus contact lenses, low-concentration atropine eye drops, corrective spectacles with peripheral defocus) * Myopic progression of at least -0.25 D in at least one eye during the year prior to inclusion (measurements documented by autorefractometer, with or without cycloplegia, or via previous optical prescriptions) or documented progression of axial length of +0.1 mm during the year prior to inclusion * Primary optical correction via spectacles (occasional use of contact lenses if applicable) or agreement to wear spectacles for at least 12 hours a day, every day * Enrolled in or a beneficiary of a social security scheme * Signed informed consent to participate in the study by the adult patient or by a person with parental authority for minor patients Exclusion Criteria: * Confirmed syndromic myopia or findings suggestive of syndromic myopia * Obvious strabismus or significant heterophoria * Corrected visual acuity \< 8/10 in at least one eye * A history of eye surgery (excluding eyelid surgery) in at least one eye * Hyperopia or non-myopic astigmatism * Anisometropia, i.e. a marked difference in correction between the two eyes * Advanced retinal disease in at least one eye, such as myopic maculopathy * Specific visual impairments in at least one eye requiring personalised treatments other than conventional corrective lenses * Intolerance to optical corrections (conventional lenses or lenses with peripheral defocus) * Patients subject to legal protection measures * Pregnant or breastfeeding women * Participation in another interventional clinical trial (drug clinical trial)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myopia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myopia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myopia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hopital Fondation A de Rothschild

    Paris, 75019, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.